May 26, 2015, New York, NY—Ludwig Cancer Research previewed today the new findings that will be presented by Ludwig scientists at this year’s American Society for Clinical Oncology Annual Meeting in Chicago, Ill., May 29 – June 2. Ludwig researchers will present recent data from early and late stage clinical trials and participate in a number of plenary and educational sessions.
“We look forward to this year’s ASCO meeting,” said David Lane, scientific director of the Ludwig Institute for Cancer Research. “Our researchers have contributed greatly to the exciting advances recently made in clinical oncology. This meeting provides an opportunity for them to build on those successes. It exposes them to data that may be of significance to their own work and gives them the opportunity to forge new partnerships with colleagues at other institutions.”
Ludwig scientists will share findings from both early- and late-stage clinical trials of treatments for several malignancies, including gastrointestinal cancers, melanoma and glioblastoma. These include reports on the effects of an approved immunotherapy—a PD-1 inhibitor—on various types of tumors whose cells are deficient in their ability to prevent gene mutations, the use of combination immunotherapy for melanoma, and a comparison of chemotherapy alone against its combination with implantable radioactive beads for the treatment of liver metastases in patients with colorectal cancer.
Click here for a comprehensive list of Ludwig’s activities at the meeting.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer research and landmark discovery for more than 40 years. Ludwig combines basic science with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing science through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.